Loading market dashboard
VentriPoint Diagnostics Ltd.
VPTDFHealthcareOTCCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Ventripoint Diagnostics Ltd. (VPT:CA) Shareholder/Analyst Call Transcript
Toronto, Canada – TheNewswire - May 25, 2026 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company ") ( TSXV:VPT; OTC:VPTDF ), a leading provider of innovative AI-powered cardiac diagnostic solutions, is pleased to provide a videoconference link for its Annual General Meeting, which will be followed by a corporate update. Shareholder Videoconference:
Toronto, Ontario, May 22, 2026 – TheNewswire - Ventripoint Diagnostics Ltd. (“ Ventripoint” or the “Corporation ”) (TSXV:VPT) is pleased to announce the closing of a non-brokered private placement of 2,800,273 units (each, a “Unit”) at a price of $0.11 per Unit for aggregate gross proceeds of $308,030 (the “Offering”), subject to TSXV Venture Exchange (the “Exchange”) acceptance. Each Unit will be comprised of one (1) common share (“Common Shares”) of the Corporation, and one (1) common share purchase warrant (“Warrants”). E ach whole Warrant will entitle the holder thereof to purchase one (1) Common Share at a price of $0.14 for a period of 24 months from the closing of the Offering.
Toronto, Ontario – TheNewswire - May 19 , 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “ Corporation ”, TSXV:VPT) announces it has received approval from the TSX Venture Exchange (“ TSXV ”) and issued of 555,699 common shares (“ Shares ”) for the payment of an aggregate of $61,217 of interest owing on certain outstanding Convertible Debentures issued by the Corporation on September 20, 2024, March 21, 2025, September 2, 2025, and October 14, 2025. The Convertible Debentures bear interest at the rate of 10% per annum, payable every 6 months. The Shares will be issued at a deemed price of $0.11 and are subject to a hold period of 4 months and one day. The issuance of the Shares will not create a control person of the Corporation. The Offering is a related party transaction within the meaning of TSXV Policy 5.9 and Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI-61-101”) as certain insiders of the Corporation received an aggregate of 15,778 Shares. The Corporation is relying on exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and (b) and 5.7(a) and (b) of MI 61-101, as the Corporation is not listed on a specified market and the fair market value of the participation in the transactions by insiders does not exceed 25% of the market capitalization of the Corporation, as determined in accordance with MI 61-101 and the fair market value of the transactions is not more than $2,500,000.
The $59B Quiet Shift Reshaping How Patients Access Care PR Newswire VANCOUVER, BC, May 12, 2026
Toronto, Ontario – TheNewswire – May 4, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT; OTC:VPTDF) will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), taking place May 12–16, 2026 in Padua, Italy. Founded in 1963, AEPC is the world's largest association in congenital cardiology, bringing together more than 1,000 specialists across 32 European countries and beyond. Its members are united by a commitment to advancing the practice of congenital and paediatric cardiology and improving outcomes for patients with heart disease.
Toronto, Canada – TheNewswire - April 28, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSX-V:VPT, OTC:VPTDF), is proud to announce that its strategic partner, Lishman Global Inc., has formally submitted Ventripoint's VMS+™ 4.0 system to China's National Medical Products Administration (NMPA), commonly referred to as the Chinese FDA, for regulatory approval. Importantly, Lishman Global has qualified for the NMPA's “green channel” pathway, an expedited review process designed to accelerate the approval of innovative medical technologies that address significant clinical needs. This designation is expected to streamline the regulatory timeline and facilitate faster access to the Chinese market.
Toronto, Ontario, April 22, 2026 - TheNewswire – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces it will satisfy debenture interest payment obligations with the issuance of common shares, subject to TSX Venture Exchange (“ TSXV ”) approval. The Corporation will issue an aggregate of 555,699 common shares (“ Shares ”) for the payment of an aggregate of $61,217 of interest owing on certain outstanding Convertible Debentures issued by the Corporation on September 20, 2024, March 21, 2025, September 2, 2025, and October 14, 2025 . The Convertible Debentures bear interest at the rate of 10% per annum, payable every 6 months. The Shares will be issued at a deemed price of $0.11, subject to the approval of TSXV, and are subject to a hold period of 4 months and one day. The issuance of the Shares will not create a control person of the Corporation. About Ventripoint Diagnostics Ltd.
Toronto, Canada – TheNewswire - April 20, 2026 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Company ”) (TSX-V:VPT, OTC:VPTDF) , is proud to announce that its proprietary VMS+™ 4.0 ( Ventripoint Medical System) technology has been awarded a Gold Medal at the 2026 Edison Awards in the Precision Health Technologies sub‑category. The Edison Awards are widely regarded as one of the most prestigious global recognitions for innovation. Judged by a peer review panel of senior executives, clinicians, engineers, and technology leaders, Gold awards are reserved for innovations that demonstrate not only technical excellence, but clear differentiation, market readiness, and the potential for sustained real‑world impact. For investors, this recognition represents independent validation of Ventripoint's strategic direction and technological leadership.
Partnership to explore expanded cardiac screening, clinical research, and AI-assisted echocardiography in Costa Rica Toronto, Ontario – TheNewswire - April 1, 2026 – Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company ") ( TSXV: VPT; OTC: VPTDF ), a leader in AI-assisted cardiac imaging solutions, today announced a collaboration with the Health Division of the Montecristo Group to explore new clinical pathways for the implementation of Ventripoint's VMS+™ cardiac imaging platform in Costa Rica.
Partnership to explore expanded cardiac screening, clinical research, and AI-assisted echocardiography in Costa Rica Toronto, Ontario – TheNewswire - April 1, 2026 – Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company ") ( TSXV: VPT; OTC: VPTDF ), a leader in AI-assisted cardiac imaging solutions, today announced a collaboration with the Health Division of the Montecristo Group to explore new clinical pathways for the implementation of Ventripoint's VMS+™ cardiac imaging platform in Costa Rica.
/PRNewswire/ -- USANewsGroup.com News Commentary - Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the
Landmark partnership deploys hub-and-spoke model to close the cardiac care gap for Indigenous and underserved populations in British Columbia — with national and global expansion planned. Toronto, Ontario – TheNewswire - March 17, 2026 - Ventripoint Diagnostics Ltd. (" Ventripoint ", “ VPT ” or the " Company "), (TSXV:VPT; OTC:VPTDF) a leader in AI-assisted cardiac imaging, today announced a partnership with First Light Health (“FLH”) to extend life-saving heart diagnostics to Indigenous and remote communities that have long faced barriers to specialist cardiac care. The collaboration marks a pivotal milestone in Ventripoint's mission to make advanced, accurate cardiac imaging universally accessible - regardless of geography.
